Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug tested for deadly Pneumonia-Sepsis combo

NCT ID NCT06669403

Not yet recruiting Disease control Sponsor: Op-T LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called OPT101 in adults hospitalized with pneumonia that has led to sepsis, a life-threatening body-wide infection. The main goal is to check if the drug is safe and how the body processes it. About 26 participants will receive either the drug or a placebo for up to 4 days while being treated in the hospital.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Denver Health and Hospital Authority

    Denver, Colorado, 80204, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.